Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

Rhea-AI Summary

Crinetics Pharmaceuticals (NASDAQ: CRNX) has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025, scheduled for June 3-5, 2025 in New York. The company's management will deliver a presentation on Thursday, June 5, 2025, at 12:50 p.m. Eastern Time. Investors can access the live and archived webcast through the Events & Presentations page in the Investors section of Crinetics' website. One-on-one meetings with management can be arranged through conference representatives.

SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.

Jefferies Global Healthcare Conference 2025
Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern Time
Webcast link: HERE

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

When is Crinetics Pharmaceuticals (CRNX) presenting at the Jefferies Global Healthcare Conference 2025?

Crinetics Pharmaceuticals will present on Thursday, June 5, 2025, at 12:50 p.m. Eastern Time.

Where can I watch Crinetics Pharmaceuticals' (CRNX) presentation at the Jefferies Conference?

The presentation can be accessed via webcast through the Events & Presentations page in the Investors section of Crinetics' website at www.crinetics.com/events.

How can investors arrange meetings with Crinetics Pharmaceuticals' (CRNX) management at the Jefferies Conference?

Investors can arrange 1x1 meetings with management by contacting their conference representative.

Where is the Jefferies Global Healthcare Conference 2025 being held?

The conference is taking place in New York, NY from June 3-5, 2025.